Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Road Ahead Unclear For Polyphor’s Intravenous Murepavadin

Executive Summary

The Swiss firm is still examining options for the iv formulation of its novel antibiotic murepavadin even after it closed its two Phase III studies on safety concerns.

You may also be interested in...



Polyphor Pulled Out Of The Mire With EnBiotix Merger

Just over three years, Polyphor's initial public offering in Switzerland raised CHF165m. Now, with just enough cash to get through the third quarter, it has been saved by a deal with US biotech EnBiotix.

Polyphor In Peril After Breast Cancer Drug Failure

Polyphor has seen its remaining asset balixafortide bite the dust and "a strategic assessment regarding the future of the company" is underway for a firm that not so long ago was seen as a rising star in the Swiss biotech sector.

Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022

In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.

Topics

Related Companies

UsernamePublicRestriction

Register

SC125562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel